Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Heidi Crayton, MD

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from non-relapsing forms (non-relapsing secondary progressive) in clinical practice, and highlight the key pathophysiological features of relapsing multiple sclerosis and the impact of progression independent of relapse activity (PIRA) after an initial demyelinating event.

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

Now Viewing

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

EP: 13.Multiple Sclerosis: Looking Toward the Future

Patients with MS typically experience significant clinical impact. How does the disease impact patients, as well as their families and other caregivers?
How are relapsing forms of MS (eg, RELAPSING MULTIPLE SCLEROSIS, PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS) differentiated in clinical practice from non-relapsing forms (non-relapsing secondary progressive multiple sclerosis)?
What are the key features of the pathophysiology of RELAPSING MULTIPLE SCLEROSIS and the impact of progression independent of relapse activity (PIRA) after a first demyelinating event?
What are the hallmark features of non-relapsing secondary progressive multiple sclerosis and what is the prevalence of non-relapsing secondary progressive multiple sclerosis seen in clinical practice?